

Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE

NCT07268560

Status RECRUITING
Sponsor Sir Run Run Shaw Hospital
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (1)

- 1. Age 18 years or older 2. Hospitalized with a diagnosis of confirmed cIAI or HAP/VAP 3. Confirmed infection with MBL-producing CRE 4. Received on label use of ATM-AVI treatment for e24 hours 5. Informed consent will be obtained or waived.

Exclusion (1)

- 1. Confirmed or suspected infection caused by Gram-negative species not expected to respond to ATM-AVI 2. Currently enrolled in an interventional clinical trial

Locations (2 total)

The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China